Molecular aspects of circadian pharmacology and relevance for cancer chronotherapy

N Ozturk, D Ozturk, I Halil Kavakli, A Okyar - International journal of …, 2017 - mdpi.com
The circadian timing system (CTS) controls various biological functions in mammals
including xenobiotic metabolism and detoxification, immune functions, cell cycle events …

Critical roles of EGFR family members in breast cancer and breast cancer stem cells: targets for therapy

LS Steelman, T Fitzgerald… - Current …, 2016 - ingentaconnect.com
The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various
cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck …

Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II

T Takayanagi, T Kawai, SJ Forrester, T Obama… - …, 2015 - Am Heart Assoc
The mechanisms by which angiotensin II (AngII) elevates blood pressure and enhances end-
organ damage seem to be distinct. However, the signal transduction cascade by which AngII …

Protein kinase Cα mediates erlotinib resistance in lung cancer cells

MB Abera, MG Kazanietz - Molecular pharmacology, 2015 - ASPET
Overexpression and mutational activation of the epidermal growth factor receptor (EGFR)
plays an important role in the pathogenesis of non–small cell lung cancer (NSCLC). EGFR …

Hepatocyte-specific Smad4 deficiency alleviates liver fibrosis via the p38/p65 pathway

M Wei, X Yan, X Xin, H Chen, L Hou… - International Journal of …, 2022 - mdpi.com
Liver fibrosis is a wound-healing response caused by the abnormal accumulation of
extracellular matrix, which is produced by activated hepatic stellate cells (HSCs). Most …

PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation

MF Salama, M Liu, CJ Clarke, MP Espaillat, JD Haley… - Oncogene, 2019 - nature.com
Mutational activation of the epidermal growth factor receptor (EGFR) is a major player in the
pathogenesis of non-small cell lung cancer (NSCLC). NSCLC patients with constitutively …

[HTML][HTML] Pharmacological drug screening to inhibit uveal melanoma metastatic cells either via EGF-R, MAPK, mTOR or PI3K

S Kassumeh, S Arrow, A Kafka, N Luft… - International Journal …, 2022 - ncbi.nlm.nih.gov
AIM To screen five potential pharmacological substances specifically targeting EGF-R,
MAPK, mTOR, or PI3K for their antiproliferative effects, possible impact on cell viability, as …

Epidermal growth factor receptor tyrosine kinase inhibitor erlotinib induces dry skin via decreased in aquaporin-3 expression

N Ikarashi, M Kaneko, T Watanabe, R Kon, M Yoshino… - Biomolecules, 2020 - mdpi.com
An adverse reaction of dry skin occurs frequently during treatment with anticancer epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). In this study, we conducted …

[PDF][PDF] Breve evolución histórica del cáncer

A Graña - Καρκίνος Carcinos, 2015 - oncosalud.pe
Breve evolución histórica del cáncer Page 32 Breve evolución histórica del cáncer Brief
historical evolution of cancer Se revisa la historia del cáncer desde tiempos remotos en la …

Chronopharmacodynamics and mechanisms of antitumor effect induced by erlotinib in xenograft-bearing nude mice

P Lin, F An, X Xu, L Zhao, L Liu, N Liu, P Wang… - Biochemical and …, 2015 - Elsevier
Receptor tyrosine kinases, mediators of a variety of critical cellular functions, contribute to
tumor progression and metastasis. The epidermal growth factor receptor (EGFR), a member …